Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States
2016 ◽
Vol 160
(1)
◽
pp. 187-196
◽
2014 ◽
Vol 147
(2)
◽
pp. 443-443
◽
2014 ◽
Vol 32
(15_suppl)
◽
pp. e11531-e11531